Abscint is a company headquartered in Belgium.
Abscint develops advanced in vivo molecular imaging diagnostics using anti-HER2 PET tracers for precision diagnostics and monitoring of HER2-positive cancers such as breast cancer.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.